# Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

> **NCT01979536** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 137 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive
- Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Crizotinib
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01979536
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-13
- **Primary completion:** 2021-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01979536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01979536, "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01979536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*